Invest in Proseek bio
Proseek Bio is an early stage start-up company seeking investors with special expertise in biotechnology fields to support the launch of our ovarian cancer detection tests.
Founded by Dr. Michelle Hill, a scientist with deep expertise in biomarker science, oncology, and clinical diagnostics, and supported by commercial molecular diagnostics expertise of Co-Founder Dr Leo Bolero.
The Proseek Bio team combines cutting-edge research with proven execution in biotech innovation.
We're clear about our mission to save lives. If that’s what drives you, let’s connect.
Our focus
Ovarian cancer is the most lethal gynecological cancers. Most cases are diagnosed late, when survival rates are poor. Current diagnostic tools are non-specific — resulting in over 80% of abdominal surgeries for suspected cancer being unnecessary.
Our Solution – OC-Triage
OC-Triage is a blood test based ovarian cancer detection test, that identifies specific glycoproteins that indicate a future likelihood of ovarian cancer.
Using Proseek Bio’s proprietary LeMBA-MS platform and specialised algorithm this test will change how women are triaged for expensive diagnostic surgery.
Seamless integration:
Works with existing mass spectrometry equipment in pathology labs.
Clinical power:
​100% sensitivity and 79% specificity in validation studies.
​
Scalable platform:
Beyond ovarian cancer, future applications include endometriosis triage and broader women’s health diagnostics.
​
Market opportunity
US$32 billion ovarian cancer diagnostics market today, projected to reach US$55B by 2033
(CAGR ~6-7%).
​Demand for Ovarian Cancer detection is growing, driven by aging populations, lifestyle risks, and environmental exposures.
Over 200,000 women in the US, and 15,000 women in Australia undergo diagnostic surgery
Traction & Validation
Proprietary technology patented and clinically validated in Brisbane research institutions (University of Queensland & QIMR Berghofer).
Strategic partnerships with leading clinical laboratories in place.
Early engagement with FDA and TGA to facilitate regulatory pathways and reimbursement.
Early market access via Research Use Only reagent kits with clinical lab partners.